More than a year and a half into Cullinan Therapeutics’ pivot from a CD19-focused oncology company to a hybrid autoimmune player, the biotech is parting ways with a pair of cancer programs.
<a href="https://www.fiercebiotech.com/biotech/cullinan-sidelines-pair-oncology-assets-amid-expansion-autoimmune-rd" hreflang="en">Cullinan sidelines pair of oncology assets amid expansion into autoimmune R&D</a>
FierceBiotech | | Fraiser Kansteiner
Topics: oncology